S56 high grade b-cell lymphoma with MYC and BCL2 and/ or BCL6 rearrangements. British Journal of Haematology. 2019;185(5):951-954. 10. Chong LC, Ben-Neriah S, Slack GW, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood advances. 2018;2(20):2755-2765. 11. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748. 12. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. New England Journal of Medicine. 2022;386(4):351-363. 13. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. New England Journal of Medicine. 2013;368(15):1408-1416. 14. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/ IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/ NCRI LY10 trial). Blood, The Journal of the American Society of Hematology. 2008;112(6):2248-2260. 15. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. Journal of clinical oncology. 2020;38(22):2519. 16. Dunleavy K, Fanale MA, Abramson JS, et al. Doseadjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology. 2018;5(12):e609-e617. 17. Abramson JS, Ruppert AS, Giri S, et al. Randomized phase II/III Study of DA-EPOCH-R+/-venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701. Blood. 2021;138:523. 18. Wilson MR, Bobillo S, Cwynarski K. CNS prophylaxis in aggressive B-cell lymphoma. Hematology. 2022;2022(1):138-145.
RkJQdWJsaXNoZXIy MTk3NTQxMg==